tradepost.ai Logo
Newsletter InsightsSEC AnalysisAI Top20 IndexPricing
Log in
Start free trial
tradepost.ai Logo

Empowering Traders with AI

Quick Links

Newsletter InsightsSEC AnalysisPricingFAQ

Legal

Privacy PolicyCookies PolicySecurity Disclosure PolicyTerms & ConditionsDisclaimer

Copyright © 2025 Dutchcode B.V. All rights reserved.

10-K/A - NutriBand Inc. (0001676047) (Filer)

Tue, May 13, 9:30 PM (61 days ago)

**Nutriband Inc. (NTRB) - Form 10-K/A Summary** **Company Overview:** Nutriband Inc. (NTRB), a Nevada-based company, filed an amendment to its annual report for the fiscal year ended January 31, 2025. The company is listed on the Nasdaq Stock Market under the ticker symbol NTRB. **Financial Performance:** The amendment does not provide updated financial figures. However, the original filing would have included revenue, net income, operating expenses, and earnings per share (EPS) for the fiscal year. **Strategic Overview and Future Outlook:** The amendment includes various exhibits related to corporate governance, equity compensation plans, and agreements with strategic partners. Key agreements include those with Kindeva Drug Delivery, L.P., and 4P Therapeutics, LLC, indicating ongoing strategic collaborations. **Market Position Changes:** As of July 31, 2024, the aggregate market value of the voting and non-voting common equity held by non-affiliates was $44,975,804. As of May 13, 2025, the company had 11,154,171 shares of common stock outstanding. **Risk Factors:** The amendment does not provide new risk factors. However, the original filing would have included discussions on market risks, operational risks, and financial risks. **Financial Condition:** The amendment does not provide updated financial condition details. The original filing would have included a comprehensive analysis of the company's financial health, liquidity, and capital resources. **Conclusion:** Nutriband Inc. continues to focus on strategic partnerships and corporate governance. The amendment reflects ongoing efforts to maintain compliance and transparency. Portfolio managers, traders, and finance professionals should review the full amendment for detailed exhibits and agreements.